利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

61 条记录 (耗时 0.03 秒)

    Indazole derivatives as CRF antagonists
    5.
    发明申请
    Indazole derivatives as CRF antagonists 审中-公开
    吲唑衍生物作为CRF拮抗剂

    公开(公告)号：US20070213373A1

    公开(公告)日：2007-09-13

    申请号：US11799605

    申请日：2007-05-02

    申请人： Richard Cournoyer ,  David Loughhead ,  Counde O'Yang

    发明人： Richard Cournoyer ,  David Loughhead ,  Counde O'Yang

    IPC分类号： A61K31/416 ,  A61K31/4439

    CPC分类号： C07D209/44 ,  C07D231/56 ,  C07D401/04

    摘要： This invention relates to compounds which are generally CRF-1 receptor antagonists and which are represented by Formula I or Formula II: wherein R3 is optionally substituted aryl or heteroaryl, R1 and R2 are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts thereof. The invention further relates to processes for preparing such compounds, to pharmaceutical compositions containing such compounds, and to methods for their use as therapeutic agents.

    摘要翻译： 本发明涉及通常为CRF-1受体拮抗剂并由式I或式II表示的化合物：其中R 3是任选取代的芳基或杂芳基，R 1， 和R 2如本说明书中所定义; 或各异构体，异构体的外消旋或非外消旋混合物或其药学上可接受的盐。 本发明还涉及制备这些化合物的方法，含有这些化合物的药物组合物及其用作治疗剂的方法。

    Ring fused pyrazole derivatives as CRF antagonists
    6.
    发明申请
    Ring fused pyrazole derivatives as CRF antagonists 失效

    公开(公告)号：US20060135555A1

    公开(公告)日：2006-06-22

    申请号：US11348036

    申请日：2006-02-06

    申请人： David Loughhead ,  Counde O'Yang

    发明人： David Loughhead ,  Counde O'Yang

    IPC分类号： A61K31/4745 ,  C07D471/02

    CPC分类号： C07D471/04 ,  C07D487/04

    摘要： This invention relates to compounds which are generally CRF-1 receptor antagonists and which are represented by Formula I or Formula II: wherein Ar is optionally substituted aryl or heteroaryl, R1-R4 are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts thereof. The invention further relates to processes for preparing such compounds, to pharmaceutical compositions containing such compounds, and to methods for their use as therapeutic agents.